24 results
424B5
VERV
Verve Therapeutics Inc
29 Nov 23
Prospectus supplement for primary offering
4:47pm
company, as applicable. These exemptions include reduced disclosure obligations regarding executive compensation and only two years of audited
424B5
VERV
Verve Therapeutics Inc
28 Nov 23
Prospectus supplement for primary offering
4:25pm
company, as applicable. These exemptions include reduced disclosure obligations regarding executive compensation and only two years of audited
S-3ASR
ehk m8zcp4
23 Sep 22
Automatic shelf registration
4:08pm
424B5
jz7k5z hjf
21 Jul 22
Prospectus supplement for primary offering
4:43pm
424B5
kkzu210
20 Jul 22
Prospectus supplement for primary offering
4:22pm
S-3
2xd11q00
1 Jul 22
Shelf registration
4:36pm
DEF 14A
cmbppr5675th3ceh
29 Apr 22
Definitive proxy
7:01am
10-K
mcsvn3h
14 Mar 22
Annual report
7:04am
10-Q
pgvvz8s 7o55j9b
12 Aug 21
Quarterly report
8:53am